Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Atlas Antibodies on the acquisition of HistoCyte Laboratories
Mandate

Vinge advises Atlas Antibodies on the acquisition of HistoCyte Laboratories

February 15, 2021 Banking and Finance Capital Markets and Public M&A M&A

Vinge advises Atlas Antibodies AB (majority owned by Patricia Industries, a part of Investor AB), in connection with its acquisition of HistoCyte Laboratories Ltd.

HistoCyte Laboratories’ portfolio of cell line materials provide control of immunohistochemical assays used in the diagnosis of cancer. The company has established a significant presence on important markets such as the UK and USA.

Closing is expected during early March 2021.

Vinge’s team consisted of Jonas Johansson together with Viktor Lennartsson (M&A), Albert Wållgren and Josefine Lanker (Banking and Finance) and Clara Sohlberg (Capital Markets and Public M&A).

Related

Vinge advises Revivo Group on the acquisition of Premator

 Revivo Group AB has acquired all the shares in Premator AB, the parent company of a group operating in the field of advanced surface treatment with extensive experience in shot blasting, anti-corrosion painting and related services. Operations are conducted in Sweden, Norway and Denmark.
September 03, 2026

Vinge advises the sellers of Berg Propulsion

 Vinge has advised the sellers in connection with the sale of Berg Propulsion to Kongsberg Maritime.
September 03, 2026

Vinge advises the sellers on the sale of Nextory to Bonnier Books

 Vinge has acted as legal adviser to the sellers in connection with Bonnier Books’ acquisition of Nextory, one of Europe’s leading streaming services for audiobooks and e-books. Bonnier Books is acquiring all shares in Nextory, and the transaction comprises Nextory’s operations in Sweden and internationally. The acquisition is a cash transaction and the parties have agreed not to disclose the purchase price. The transaction is subject to customary regulatory approvals.
September 02, 2026